Ardelyx (ARDX) vs Janux Therapeutics (JANX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Janux Therapeutics (JANX) has outperformed Ardelyx (ARDX) over the past year, losing 23.6% versus a loss of 35.4%. Over five years, ARDX leads with a +202.8% price change compared with -12.4% for JANX. Janux Therapeutics is the larger company by market cap ($1.15 billion vs $837.8 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | JANX |
|---|---|---|
| Share price | $3.25 | $18.76 |
| Market cap | $837.82M | $1.15B |
| 1-day change | -0.76% | +1.41% |
| YTD return | -43.91% | +34.06% |
| 1-year return | -35.38% | -23.55% |
| 5-year return | +202.78% | -12.45% |
| Forward P/E | 11.17 | — |
| EPS (TTM) | $-0.23 | $-1.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $35.34 |
| 52-week low | $3.18 | $12.12 |
| Distance from 52-week high | -61.37% | -46.92% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +297.53% | +93.18% |
| Average volume | 4.17M | 845.95K |
| Shares outstanding | 258.19M | 61.14M |
| Employees | 489 | 113 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JANX has outperformed ARDX by 11.8 percentage points over the past year.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 113 employees
ARDX vs JANX FAQ
Which is bigger, Ardelyx or Janux Therapeutics?
Janux Therapeutics (JANX) is larger, with a market capitalization of $1.15B compared with $837.82M for Ardelyx (ARDX).
Which stock has performed better over the past year, ARDX or JANX?
JANX returned -23.55% over the past 12 months, compared with -35.38% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and Janux Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.